Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

This study has been terminated.
(Funding not available)
Novartis Pharmaceuticals
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota Identifier:
First received: January 25, 2010
Last updated: November 6, 2012
Last verified: November 2012
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of tumor angiogenesis (a fundamental step in the transition of tumors from a dormant state to a malignant one). Bortezomib triggers cell death in pancreatic cancer cells but the mechanism is not well defined but has been determined to be cytostatic. Combining these two drugs may work together in the treatment of pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer
Drug: Bortezomib
Drug: Panobinostat
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination

Resource links provided by NLM:

Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Progression-Free Survival [ Time Frame: Up to 1 Year ]
    Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.

Secondary Outcome Measures:
  • Number of Participants by Tumor Response [ Time Frame: Up to 1 Year ]
    Number of patients whose tumor has responded to study therapy is determined using Response Evaluation Criteria In Solid Tumors. Progressive Disease (PD) is assessed if the sum of the diameters has increased by ≥ 20% and ≥ 5 mm from nadir (including baseline if it is the smallest sum). Objective response is measured by tumor reduction as defined in the RECIST criteria. Tumor shrinkage must be at least 30% to qualify as an objective response.

  • Duration of Response [ Time Frame: Up to 1 Year ]
    Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed Complete or Partial Response as defined by RECIST criteria).

Enrollment: 7
Study Start Date: September 2010
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pancreatic Cancer Patients
Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
Drug: Bortezomib
1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
Other Name: Velcade
Drug: Panobinostat
20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Other Name: LBH589


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological diagnosis of locally advanced or metastatic pancreatic cancer (except neuroendocrine tumors, but including ampullary cancer) with progression after standard first line therapy that included gemcitabine (single agent or combination)
  • Measurable disease on computated tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • At least 28 days from previous systemic therapy, including investigational agents and 1st dose of study treatment and recovered from any acute toxic effects of that treatment before study enrollment.
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 - Ability to provide written consent
  • Must meet hematology and biochemistry laboratory criteria within 14 days of study enrollment:

    • Neutrophil count >1500/mm^3
    • Platelet count >100,000/mm^L
    • Hemoglobin > or = 9 g/dL
    • Aspartate aminotransferase (AST/SGOT) or Alanine transaminase (ALT/SGPT) < or = 2.5 times upper limit of normal (ULN)or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement
    • Serum bilirubin < or = 1.5 x ULN
    • Serum creatinine < or = 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min
    • Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal (LLN)
    • Serum phosphorus > or = LLN
    • Serum potassium > or = LLN
    • Serum sodium ≥ LLN
    • Serum magnesium ≥ LLN
    • Serum albumin ≥ LLN or 3g/dl
    • Patients with any elevated Alkaline Phosphatase due to bone metastasis can be enrolled
  • Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstration left ventricular ejection fraction (LVEF) > or = 50%
  • Normal thyroid function within normal limits. Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.
  • Women of childbearing potential (WOCBP) must have a negative pregnancy tests within 7 days of study treatment administration and willing to use 2 methods of contraception

Exclusion Criteria:

  • > 1 prior systemic treatment regimen for pancreatic cancer
  • Prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors or valproic acid for treatment of cancer
  • Anyone needing valproic acid for any medical condition during the study or 5 days prior to panobinostat treatment
  • Impaired cardiac function

    • Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular block)
    • Presence of atrial fibrillation (ventricular heart rate >100 bpm)
    • Previous history angina pectoris or acute myocardial infarction (MI) within 6 months of study enrollment
    • Congestive heart failure (New York Heart Association functional classification III-IV) or baseline MUGA/Echo shows LVEF < 50%
  • Uncontrolled hypertension defined as hypertensive blood pressure of SBP > 140 or DBP > 90, despite antihypertensive medications
  • History of deep vein thrombosis (DVT), pulmonary emboli or other blood clotting abnormality within 3 months of study enrollment
  • Ongoing need for anti-coagulation therapy except daily low dose aspirin (≤ 100 mg/day) or low molecular weight heparin
  • Concomitant use of drugs with risk of causing torsades de pointes
  • Anyone with unresolved diarrhea > or = grade 2 at time of enrollment
  • Impairment of gastrointestinal function or disease that may significantly alter the absorption of panobinostat
  • Grade 2 or greater peripheral neuropathy within 14 days of enrollment
  • Serious concomitant medical or psychiatric disorders (e.g., active infection, uncontrolled diabetes)
  • Patients who have received chemotherapy, any investigational agent or undergone major surgery < 4 weeks prior to starting study drug
  • Male patients whose sexual partners are WOCBP and not using double method of contraception during the study and 3 months following.
  • Known positivity for human immunodeficiency virus (HIV) or hepatitis C
  • Hypersensitivity to bortezomib, boron or mannitol History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01056601

United States, Minnesota
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Novartis Pharmaceuticals
Millennium Pharmaceuticals, Inc.
Principal Investigator: Arkadiusz Dudek, MD Masonic Cancer Center, University of Minnesota
  More Information

Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT01056601     History of Changes
Other Study ID Numbers: 2009LSUC012
X05302 ( Other Identifier: Millennium Pharmaceuticals, Inc. )
Study First Received: January 25, 2010
Results First Received: July 28, 2011
Last Updated: November 6, 2012

Keywords provided by Masonic Cancer Center, University of Minnesota:
cancer of pancreas
neoplasms, pancreas
alpha-cell tumor
beta-cell tumor

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Histone Deacetylase Inhibitors processed this record on April 28, 2017